Diabetes Drug's cholesterol mystery: new study aims to unravel the why

NCT ID NCT03269058

Completed Knowledge-focused Sponsor: Centre Hospitalier Universitaire Dijon Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study looks at why dapagliflozin, a diabetes drug, can raise 'bad' cholesterol levels. Researchers will track how the body makes and clears cholesterol in 28 adults with type 2 diabetes over 6 months. Half the participants will get dapagliflozin, the other half a placebo. The goal is to understand the problem so doctors can better manage cholesterol in these patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Dapagliflozin
What this could lead to: If successful, this study could help doctors choose the right cholesterol-lowering drugs for people with type 2 diabetes who take dapagliflozin.
What could go wrong: This is a small, early-phase study with only 28 participants, so results may not apply to everyone. It aims to understand mechanisms, not prove a new treatment works.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ORAL ANTIDIABETICS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ORAL ANTIDIABETICS TYPE 2 DIABETES

Contacts and locations

Locations

CHU Dijon Bourgogne

Dijon, 21079, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.